Premium
Treatment of Peri‐Implant Defects in the Rabbit's Tibia with Adipose or Bone Marrow‐Derived Mesenchymal Stems Cells
Author(s) -
Erdogan Özgür,
Supachawaroj Nuttawut,
Soontornvipart Kumpanart,
Kheolamai Pakpoom
Publication year - 2016
Publication title -
clinical implant dentistry and related research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.338
H-Index - 85
eISSN - 1708-8208
pISSN - 1523-0899
DOI - 10.1111/cid.12378
Subject(s) - adipose tissue , mesenchymal stem cell , implant , bone marrow , tibia , bone healing , medicine , anatomy , pathology , surgery
Background Mesenchymal stem cell ( MSC ) treatment in conjunction with bone graft materials or space filler can be an alternative to autogenous bone grafts in the treatment of peri‐implant bone defects. Purpose To evaluate the success of bone regeneration capacity of adipose‐derived and bone marrow‐derived MSCs for the treatment of peri‐implant bone defects when applied with a beta‐tricalcium phosphate/collagen‐based scaffold. Material and Methods Forty implants were placed into the tibiae of 10 rabbits bilaterally. Surgical defects created around the implants were treated with one the following treatment modalities: 1) adipose‐derived MSC transplanted scaffold + collagen membrane; 2) bone marrow‐derived MSC transplanted scaffold + collagen membrane; 3) autogenous bone + collagen membrane; and 4) collagen membrane only. The bone regeneration capacity of each technique was determined by histomorphometry, micro‐ CT , and measuring the implant stability by resonance frequency analysis. Results One limb of one rabbit was excluded because of fracture, and another limb was excluded because of infection. All parameters on 36 implants revealed that both sources of MSC can form equivalently new bone that is comparable with autogenous bone. The defects treated with membrane only had significantly less bone formation compared with other groups. Conclusion Both adipose‐derived and bone marrow‐derived MSC treatments are feasible alternatives to autogenous bone grafts in the treatment of peri‐implant osseos defects.